Price (delayed)
$7.75
Market cap
$445.66M
P/E Ratio
27.68
Dividend/share
$0.2
EPS
$0.28
Enterprise value
$380.51M
kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology
Special dividends are included in TTM DPS and yield
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.